These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
720 related articles for article (PubMed ID: 19243424)
41. A randomized, double-blind, placebo-controlled, parallel-group study of rufinamide as adjunctive therapy for refractory partial-onset seizures. Biton V; Krauss G; Vasquez-Santana B; Bibbiani F; Mann A; Perdomo C; Narurkar M Epilepsia; 2011 Feb; 52(2):234-42. PubMed ID: 20887365 [TBL] [Abstract][Full Text] [Related]
42. The SKATE study: an open-label community-based study of levetiracetam as add-on therapy for adults with uncontrolled partial epilepsy. Steinhoff BJ; Somerville ER; Van Paesschen W; Ryvlin P; Schelstraete I Epilepsy Res; 2007 Aug; 76(1):6-14. PubMed ID: 17681453 [TBL] [Abstract][Full Text] [Related]
43. Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures. Krauss GL; Serratosa JM; Villanueva V; Endziniene M; Hong Z; French J; Yang H; Squillacote D; Edwards HB; Zhu J; Laurenza A Neurology; 2012 May; 78(18):1408-15. PubMed ID: 22517103 [TBL] [Abstract][Full Text] [Related]
44. Efficacy and safety of conversion to monotherapy with eslicarbazepine acetate in adults with uncontrolled partial-onset seizures: a randomized historical-control phase III study based in North America. Sperling MR; Harvey J; Grinnell T; Cheng H; Blum D; Epilepsia; 2015 Apr; 56(4):546-55. PubMed ID: 25689448 [TBL] [Abstract][Full Text] [Related]
45. Double-blind placebo-controlled trial of adjunctive levetiracetam in pediatric partial seizures. Glauser TA; Ayala R; Elterman RD; Mitchell WG; Van Orman CB; Gauer LJ; Lu Z; Neurology; 2006 Jun; 66(11):1654-60. PubMed ID: 16641323 [TBL] [Abstract][Full Text] [Related]
46. Open-label, long-term safety study of zonisamide administered to children and adolescents with epilepsy. Shinnar S; Pellock JM; Conry JA Eur J Paediatr Neurol; 2009 Jan; 13(1):3-9. PubMed ID: 18343174 [TBL] [Abstract][Full Text] [Related]
47. Pregabalin or placebo used adjunctively with levetiracetam in refractory partial-onset epilepsy: a post hoc efficacy and safety analysis in combined clinical trials. Uthman BM; Almas M; Emir B; Giordano S; Leon T Curr Med Res Opin; 2011 Jul; 27(7):1285-93. PubMed ID: 21561392 [TBL] [Abstract][Full Text] [Related]
48. Randomized, double-blind, placebo-controlled trial of ezogabine (retigabine) in partial epilepsy. French JA; Abou-Khalil BW; Leroy RF; Yacubian EM; Shin P; Hall S; Mansbach H; Nohria V; Neurology; 2011 May; 76(18):1555-63. PubMed ID: 21451152 [TBL] [Abstract][Full Text] [Related]
49. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study. Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648 [TBL] [Abstract][Full Text] [Related]
50. Psychiatric and cognitive adverse events: A pooled analysis of three phase III trials of adjunctive eslicarbazepine acetate for partial-onset seizures. Andermann E; Biton V; Benbadis SR; Shneker B; Shah AK; Carreño M; Trinka E; Ben-Menachem E; Biraben A; Rocha F; Gama H; Cheng H; Blum D; Epilepsy Behav; 2018 May; 82():119-127. PubMed ID: 29604484 [TBL] [Abstract][Full Text] [Related]
51. [Exalief as a newer antiepileptic drug for adjunctive therapy of refractory partial-onset seizures]. Ermolenko NA; Buchneva IA Zh Nevrol Psikhiatr Im S S Korsakova; 2014; 114(11):129-34. PubMed ID: 25629136 [TBL] [Abstract][Full Text] [Related]
52. Pregabalin add-on therapy using a flexible, optimized dose schedule in refractory partial epilepsies: a double-blind, randomized, placebo-controlled, multicenter trial. Lee BI; Yi S; Hong SB; Kim MK; Lee SA; Lee SK; Shin DJ; Kim JM; Song HK; Heo K; Lowe W; Leon T Epilepsia; 2009 Mar; 50(3):464-74. PubMed ID: 19222545 [TBL] [Abstract][Full Text] [Related]
53. [Perampanel in treatment of refractory partial epilepsy in adolescents and adults: results of international multicenter randomized, double-blind, placebo-controlled phase III studies]. Belousova ED Zh Nevrol Psikhiatr Im S S Korsakova; 2014; 114(8):32-8. PubMed ID: 25345628 [TBL] [Abstract][Full Text] [Related]
54. Long-term safety and efficacy following conversion to eslicarbazepine acetate monotherapy in adults with focal seizures. Chung S; Sinha SR; Shah A; Stern JM; Cheng H; Jung J; Grinnell T; Blum D Epilepsy Res; 2019 Jul; 153():59-65. PubMed ID: 30999260 [TBL] [Abstract][Full Text] [Related]
55. Efficacy and safety of eslicarbazepine acetate monotherapy for partial-onset seizures: Experience from a multicenter, observational study. Toledano R; Jovel CE; Jiménez-Huete A; Bayarri PG; Campos D; Gomariz EL; Giráldez BG; García-Morales I; Falip M; Agredano PM; Palao S; Prior MJAA; Pascual MRQ; Navacerrada FJ; González FJL; Ojeda J; Sáez AA; Bermejo PE; Gil-Nagel A Epilepsy Behav; 2017 Aug; 73():173-179. PubMed ID: 28641170 [TBL] [Abstract][Full Text] [Related]
56. Pregabalin add-on treatment in patients with partial seizures: a novel evaluation of flexible-dose and fixed-dose treatment in a double-blind, placebo-controlled study. Elger CE; Brodie MJ; Anhut H; Lee CM; Barrett JA Epilepsia; 2005 Dec; 46(12):1926-36. PubMed ID: 16393158 [TBL] [Abstract][Full Text] [Related]
57. Efficacy and safety of perampanel in patients with drug-resistant partial seizures after conversion from double-blind placebo to open-label perampanel. Montouris G; Yang H; Williams B; Zhou S; Laurenza A; Fain R Epilepsy Res; 2015 Aug; 114():131-40. PubMed ID: 26088896 [TBL] [Abstract][Full Text] [Related]
58. Efficacy and safety of eslicarbazepine acetate versus controlled-release carbamazepine monotherapy in newly diagnosed epilepsy: A phase III double-blind, randomized, parallel-group, multicenter study. Trinka E; Ben-Menachem E; Kowacs PA; Elger C; Keller B; Löffler K; Rocha JF; Soares-da-Silva P Epilepsia; 2018 Feb; 59(2):479-491. PubMed ID: 29369348 [TBL] [Abstract][Full Text] [Related]